Saniona, a research and development company, engages in the development of drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases and treatment of pain. It has a portfolio of various drug candidates in pre-clinical and clinical stages. The Company's products include Tesofensine, a triple monoamine reuptake inhibitor, which is in Phase III clinical trial to treat obesity; Tesomet, a fix-dose combination of tesofensine and metoprolol that is in Phase II clinical trials for the treatment of metabolic diseases and prader-wills syndromes; NS2359, a triple monoamine reuptake inhibitor that is in Phase II clinical trial for cocaine addiction; and CAD-1883 that is in Phase I clinical trial for ataxia/tremor.
|Employees (est.) (Feb 2019)||22|
|Share Price (May 2020)||KR27.5||(+9%)|
Market capitalization (27-May-2020)
Closing stock price (27-May-2020)
When was Saniona founded?
Saniona was founded in 2011.
How many employees does Saniona have?
Saniona has 22 employees.
Who are Saniona competitors?
Competitors of Saniona include BioSpecifics Technologies, Fibrocell Science and Gilead Sciences.
Where is Saniona headquarters?
Saniona headquarters is located at 154 Baltorpvej, Ballerup.
Where are Saniona offices?
Saniona has an office in Ballerup.
How many offices does Saniona have?
Saniona has 1 office.
Receive alerts for 300+ data fields across thousands of companies